Navigation Links
CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price
Date:8/26/2008

WOBURN, Mass., Aug. 26 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) announces the release of the Maestro(TM) EX In Vivo Imaging System. The new system incorporates CRi's state-of-the-art FLEX technology and becomes the entry-level instrument of choice for in vivo fluorescence imaging.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080826/NETU054 )

FLEX technology represents a significant advancement of CRi's unique solid-state tunable optics that for the first time enables both broad- and narrow-band spectral imaging at the click of a button. The user can select high optical throughput for reduced experiment times or increased spectral resolution for enhanced separation of similar fluorescent labels.

Accurate spectral detection is essential for quantitative signal unmixing. Patent-pending Maestro software tools complement the improved optical capabilities of the Maestro EX by ensuring accurate and automated characterization of fluorescent signals in spectrally complex samples. Dynamic Contrast Enhancement (DyCE(TM)) is available as an accessory. DyCE is a revolutionary all-optical anatomic imaging solution for mice that also helps eliminate signals from non-specific binding in much less time than conventional means-by as much as 90% less time.

"You will be able to detect and measure more markers in your mouse model and resolve even extremely closely spaced and overlapping emission signals." explains James Mansfield, Director of Multispectral Imaging Systems at CRi.

The Maestro EX enables more precise detection and quantitation of molecular probes in live animals and complements the automated high-throughput Maestro 2 imaging system, by providing comparable imaging performance in a design intended for lower-throughput manual operation.

By providing unprecedented accuracy, sensitivity, and flexibility, along with powerful and intuitive software, the Maestro EX solidifies CRi's reputation as the industry's leading provider of in vivo fluorescence imaging systems.

Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based biomedical imaging company providing innovative optical imaging solutions for more than 20 years. CRi's multidisciplinary team is dedicated to providing comprehensive solutions that enable our customers to produce breakthroughs in research and medical care. CRi technology helps extract new disease-specific information from biological and clinical samples in the physiological, morphological, and biochemical context of intact tissues and organisms.

With over 80 patents pending and issued, CRi's award-winning innovations are being utilized around the world in a wide range of settings, ranging from academic researcher to pharmaceutical drug development to clinical medicine. CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art manufacturing facility. We are able to rapidly design and manufacture system- level solutions for a variety of growing market applications.

Visit http://www.cri-inc.com/maestro-pr to find out more about the Maestro EX system.

For more information visit our website at http://www.cri-inc.com or contact:

Ross Nakatsuji

CRi Marketing/Sales Group Leader

35-B Cabot Road, Woburn, MA 01801 USA

(P) 1-781-935-9099, extension 177, (C) 1-781-405-4000,

(E) rnakatsuji@cri-inc.com


'/>"/>
SOURCE Cambridge Research & Instrumentation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase of ... and an increase of 1.2% on an adjusted pro forma, ... quarter were $0.52 reported, a decrease of 47.5% from the ... over the prior year period , The Company increases ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
Breaking Medicine Technology:
(Date:5/3/2016)... , ... May 03, 2016 , ... Finding the right way to address a patient’s ... healthcare industry is now getting on board. , “You do the right thing, at the ... of care goes down, not up,” said Leonard M. Fromer, MD, FAAFP, from Group Practice ...
(Date:5/3/2016)... ... ... LunchSkins is changing the future of ocean plastic pollution by launching ... baggies. The mission-driven bags give back to global leaders in the fight to end ... is all about reducing global plastic waste and we’ve teamed up with some powerful ...
(Date:5/3/2016)... ... 2016 , ... Dave Newberry, broker/owner of Newberry Realty, recently announced his office ... luncheon on Friday, May 20. “We have raised over $1,000 for the table to ... Newberry. , PICC is a local Kent, WA, clinic that cares for drug-exposed babies ...
(Date:5/3/2016)... ... May 03, 2016 , ... The ... issued by the Office of the National Coordinator for Health IT (ONC) with ... action when necessary, including suspending and terminating certifications issued to Complete EHRs and ...
(Date:5/2/2016)... ... ... It has just been announced Jack Uldrich, renowned futurist and ... of May. , Uldrich is the author of 11 books and a regular guest ... the Science Channel’s FutureScape and Discovery Channel’s Inside Out. , Known the world over ...
Breaking Medicine News(10 mins):